TY - JOUR
T1 - Integrins and adhesion molecules as targets to treat inflammatory bowel disease
AU - Bravatà, Ivana
AU - Allocca, Mariangela
AU - Fiorino, Gionata
AU - Danese, Silvio
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.
AB - Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.
UR - http://www.scopus.com/inward/record.url?scp=84949483492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949483492&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2015.11.007
DO - 10.1016/j.coph.2015.11.007
M3 - Article
C2 - 26687159
AN - SCOPUS:84949483492
VL - 25
SP - 67
EP - 71
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
ER -